Affitech - Advancing Human Antibody Therapeutics
Antibody therapeutics have started to deliver major patient benefits worldwide. Affitech is in the forefront of discovering and developing the new generation of drugs based on fully human antibodies for cancer and other key disease areas. We do this by utilizing our fully integrated antibody library and proprietary screening platforms, and in partnership with pharma and biotechnology companies as well as through the development of our own exciting pipeline of product candidates.
Our Scientific Approach
Affitech has established two innovative technology platforms for discovering antibodies against validated targets. One of these technologies involves diseased or transfected cells for the identification of antibodies as well as their cognate targets when unknown. Affitech is utilizing its scientific and development expertise in building its own pipeline of cancer therapies as well as forming discovery and development partnership with various pharma and biotechnology companies.
|
|
